Medline Inc. announces pricing of secondary offering of Class A common stock
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Medline (Nasdaq: MDLN) priced a secondary offering of 60,000,000 Class A common shares to be sold by existing stockholders. The public price is $35.50 per share, and the sellers granted underwriters a 30-day option to buy up to 9,000,000 additional shares. Medline is not selling shares and will receive no proceeds. The company expects the offering to close on November 23, 2026, subject to customary closing conditions.
Medline and Medline Holdings agreed to buy back $200 million of Class A shares and Medline Holdings limited partnership interests directly from the sellers at the price paid by the underwriters. The repurchase is expected to close alongside the offering and depends on the offering closing, but not the reverse.
Positive
- Minor point$200 million agreed repurchase covers Class A shares and partnership interests at the price paid by the underwriters
- Minor point. Forward-looking: it has not happened yet and may not happen.Class B shares will be canceled one-for-one, for no extra payment, if corresponding partnership interests are repurchased
Negative
- Minor point$200 million repurchase depends on the secondary offering closing; the offering does not depend on the repurchase
News Explained
For any repurchased Medline Holdings limited partnership interests (“Common Units”), the seller must also transfer an equal number of Medline Class B shares to Medline for no additional consideration; when the repurchase closes, Medline will cancel and retire those Class B shares.
Key Figures
- Offering shares
- 60,000,000 shares
- Secondary offering by selling stockholders
- Offering price
- $35.50 per share
- Price to the public
- Underwriters’ option
- Up to 9,000,000 additional shares; 30-day option
- Granted by the selling stockholders
- Repurchase
- $200 million
- Expected concurrent private transaction at the offering price
- Expected offering close
- November 23, 2026
- Subject to customary closing conditions
Previous Offering Reports
-
Launched this same secondary offering, including the planned repurchase; today’s announcement sets its price.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
secondary offering financial
non-underwritten transaction financial
prospectus regulatory
registration statement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
NORTHFIELD, Ill., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today the pricing of its secondary offering of 60,000,000 shares of Medline’s Class A common stock by certain selling stockholders affiliated with Blackstone Inc., The Carlyle Group Inc., Hellman & Friedman LLC along with GIC Private Limited and its managed affiliate and a wholly owned subsidiary of the Abu Dhabi Investment Authority (collectively, the “Selling Stockholders”) at a price to the public of
Medline is not selling any shares of Class A common stock in the Offering and will not receive any of the proceeds from the sale.
Goldman Sachs & Co. LLC, Morgan Stanley, BofA Securities and J.P. Morgan are acting as global coordinators and joint bookrunning managers. Barclays, Citigroup, Deutsche Bank Securities, Jefferies, UBS Investment Bank, Evercore ISI, BMO Capital Markets, BNP Paribas, MUFG, RBC Capital Markets, Santander, Societe Generale, TD Cowen, Wells Fargo Securities, Wolfe | Nomura Alliance, Leerink Partners, Macquarie Capital, Mizuho, Piper Sandler, Truist Securities and William Blair are acting as bookrunning managers, and Blackstone Capital Markets, Carlyle, Baird, Rothschild & Co, Stifel, BTIG, ING, IMI – Intesa Sanpaolo, NCMG, Perella Weinberg, Academy Securities, Blaylock Van, LLC, C.L. King & Associates, Drexel Hamilton, Loop Capital Markets, Mischler AmeriVet, R. Seelaus & Co., LLC, Ramirez & Co., Inc., Siebert Williams Shank and Tigress Financial Partners are acting as co-managers for the Offering.
The Offering of these securities is being made only by means of a prospectus. When available, copies of the prospectus relating to this Offering may be obtained from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at 1-866-471-2526, or by email at prospectus-ny@ny.email.gs.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014 or by email at prospectus@morganstanley.com; BofA Securities, Attention: Prospectus Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001 or by email at dg.prospectus_requests@bofa.com; and J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com.
In addition, as previously announced, Medline and Medline Holdings, LP (“Medline Holdings”) have agreed to repurchase an aggregate of
A registration statement relating to these securities was filed with, and declared effective by, the Securities and Exchange Commission (the “SEC”). This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Medline
Medline is the largest provider of medical-surgical products and supply chain solutions serving all points of care. Through its broad product portfolio, resilient supply chain and leading clinical solutions, Medline helps healthcare providers improve their clinical, financial and operational outcomes. Headquartered in Northfield, Ill., the company employs more than 45,000 people worldwide and operates in more than 100 countries.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Words such as “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “foreseeable,” “intend,” “may,” “plan,” “potentially,” “predict,” “project,” “seek,” “should,” “will,” or “would,” or similar conditional or future expressions, are intended to identify forward-looking statements. Examples of forward-looking statements include, but are not limited to, statements related to Medline’s industry, business strategy, costs, and cost savings, goals and expectations, market position, future operations, margins, profitability, annual guidance, and other financial and operating information. The forward-looking statements are based on management’s current expectations and are subject to various risks, uncertainties, and changes in circumstances, many of which are beyond Medline’s control, that could cause actual results to differ materially.
Although we believe that the assumptions underlying the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. Accordingly, there are or will be important factors that may cause actual results to differ from expected results. These factors include but are not limited to those described under “Risk Factors” in Medline’s registration statement on Form S-1, as amended, relating to the Offering and “Item 1A. Risk Factors” in Medline’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed with the SEC, as such factors may be updated from time to time in Medline’s periodic filings with the SEC. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Medline’s filings with the SEC. Except as otherwise required by law, we disclaim any intent or obligation to update any “forward-looking statement” made in this press release to reflect changed assumptions, the occurrence of unanticipated events, or changes to future operating results over time.
Contacts:
Investor relations:
Karen King
Global Head, Investor Relations
Patrick Flaherty
Director, Investor Relations
+1.847.247.7222
IR@medline.com
Media relations:
Ben Fox
Vice President, Corporate Communications
+1.224.327.9999
media@medline.com
Source: Medline Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How does Medline’s $200 million buyback relate to the secondary offering?
Medline and Medline Holdings agreed to repurchase $200 million of Class A shares and limited partnership interests directly from the selling stockholders at the price paid by the underwriters. The repurchase depends on the offering closing and will count toward Medline’s existing buyback program. Medline’s board audit committee approved the repurchase.